"The introduction of our first bispecific candidate for inflammatory diseases, CDX-622, builds on our leadership in mast cell biology,” said Anthony Marucci, Co-founder, President and Chief Executive ...

The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) ...

Canada Inc. said it is disappointed and strongly disagrees with Canada’s Drug Agency’s Final Recommendation for Ebglyss, ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Glamour magazine sought clarity from Dr Donald Grant, a GP and Senior Clinical Advisor at The Independent Pharmacy, who ...

BTIG analyst Julian Harrison upgraded the rating on Aclaris Therapeutics (ACRS – Research Report) to a Buy yesterday, setting a price target of ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

When it comes to medical marketing, some campaigns are built around celebrity spokespeople while others opt for first-person ...

Gender bias in cardiac treatment guidelines is putting women at risk because ... BSI-045B just wrapped up a single-arm, proof-of-concept phase IIa study in moderate to severe atopic dermatitis.

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...